Verastem appoints Michael P. Bailey CEO effective Jan. 1, 2027

Verastem named Michael P. Bailey president and CEO, effective Jan. 1, 2027, succeeding Daniel Paterson, who will retire. Bailey has served on Verastem’s board since May 2026; he previously ran AVEO Pharmaceuticals as president and CEO from 2015. Paterson will remain an advisor and continue as a board member. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via (Ref. ID: 202610140601BIZWIRE_USPR_____20261014_BW530284) on October 14, 2026, and is solely responsible for the information contained therein. (C)